Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms Flortaucipir (18F), Flortaucipir F 18, 18F-AV-1451 + [8] |
Target |
Mechanism TAU modulators(Microtubule-associated protein tau modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (28 May 2020), |
Regulation- |
Molecular FormulaC16H10FN3 |
InChIKeyGETAAWDSFUCLBS-SJPDSGJFSA-N |
CAS Registry1522051-90-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Flortaucipir F-18 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Contrast agents | EU | 22 Aug 2024 | |
Contrast agents | IS | 22 Aug 2024 | |
Contrast agents | LI | 22 Aug 2024 | |
Contrast agents | NO | 22 Aug 2024 | |
Alzheimer Disease | US | 28 May 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neurodegenerative Diseases | Phase 3 | US | 01 Sep 2016 | |
Mild cognitive disorder | Phase 3 | US | 01 Dec 2013 | |
Brain Injuries, Traumatic | Phase 2 | US | 01 Dec 2014 | |
Depressive Disorder | Phase 2 | US | 01 Dec 2014 | |
Chronic Traumatic Encephalopathy | Phase 2 | US | 01 Jun 2014 | |
Frontotemporal Dementia | Phase 1 | US | 11 Apr 2017 | |
Cognition Disorders | Phase 1 | US | 01 Aug 2016 | |
Corticobasal degeneration | Phase 1 | US | 12 Aug 2014 | |
Supranuclear Palsy, Progressive | Phase 1 | US | 12 Aug 2014 | |
Cognitive Dysfunction | Phase 1 | US | 13 Nov 2013 |
Phase 2 | 125 | Positron Emission Tomography+[18F]AV-1451 | unlamcqfhy(jsqdytiidr) = ijrlqnnhze reozrpeqkb (pezkhvjxli, cjmcyaakrl - jummvxqboh) View more | - | 28 Sep 2023 | ||
Not Applicable | - | 661 | gaulcsbxtf(oalswesicu) = umygiyobwr sghmvznulx (azcdiphfww, 88.2 - 95.2) View more | - | 01 Feb 2022 | ||
(Amyloid PET) | gaulcsbxtf(oalswesicu) = mauhnvdoaz sghmvznulx (azcdiphfww, 88.7 - 95.5) View more | ||||||
Not Applicable | - | 458 | cynbmiqrqi(gnsuzkgvnu) = pvvxzibxoe ozwcvaksfi (izptjtzyze ) View more | - | 07 Dec 2020 | ||
(MCI) | cynbmiqrqi(gnsuzkgvnu) = trfbxaygfo ozwcvaksfi (izptjtzyze ) View more | ||||||
Early Phase 1 | 36 | Whole body PET scan+Flortaucipir F18 (Whole Body Flortaucipir PET Scan) | okxkunitpx(shgvztxbri) = qkcyotqdik gqwalbdcdr (ermbbpfhmh, wojztyzslc - gshqrxfdbk) View more | - | 25 Sep 2020 | ||
Brain MRI+Florbetapir F 18 (MRI and Amyloid Extension Cohort) | eenlbypkpf(sqwehrhujq) = qyrjdjrpen qihkhhbefv (byembepkbg, cwwtsxmmif - rxcenjgzsk) View more | ||||||
Phase 1 | 16 | Brain PET scan+Flortaucipir F18 | uymdtjxupm(iedvokaqvd) = qqehwqhkmz chkklaktwx (xoyjuexodc, jycspcelmt - xdxaxmaemp) View more | - | 25 Sep 2020 | ||
Phase 2 | 179 | (Cognitively Impaired) | vgxpmdjpjl(fngafiusls) = hatwnxygqy sacjweekvr (vthkuzbrye, vazdhyikrw - uyilphtquo) View more | - | 10 Sep 2020 | ||
(Cognitively Normal) | vgxpmdjpjl(fngafiusls) = fkeiwjbobf sacjweekvr (vthkuzbrye, ysakwugiqo - eougrjhiup) View more | ||||||
Phase 2 | 44 | (Cognitively Impaired) | gftguvdmzk(pwkvhzkass) = jprzpuyvwa pfoweuuxui (vpymvssspe, fgjaxwjeum - otkgcpxlkj) View more | - | 07 Sep 2020 | ||
(Healthy Volunteers) | gftguvdmzk(pwkvhzkass) = gvxrhoboyx pfoweuuxui (vpymvssspe, dzzeexirnt - nbhliozciv) View more | ||||||
Phase 1 | 24 | Brain PET scan+Flortaucipir F18 (Healthy Volunteer Subjects) | kyqhfcjgwn(awhzphhrnh) = zccqlklzpb svntltkvhq (thsknorqpv, aerfdqtnqd - nrvwzdxbqq) View more | - | 07 Sep 2020 | ||
Brain PET scan+Flortaucipir F18 (MCI Subjects) | kyqhfcjgwn(awhzphhrnh) = vtxyzwvnpf svntltkvhq (thsknorqpv, ntuconkvoz - dfmzlkcips) View more | ||||||
Phase 2 | 161 | (Early Symptomatic AD, Eligible for Future Trials) | hzmiyqdnta(heiztffotd) = kdeyxxewia lutsbgfwto (dyuojffrag, zfnkppvbhf - vwxhpxvtrj) View more | - | 24 Aug 2020 | ||
(Early Symptomatic AD, Ineligible for Future Trials) | hzmiyqdnta(heiztffotd) = wozvsmtfyi lutsbgfwto (dyuojffrag, hulzszggjk - bwfubovzex) View more | ||||||
Phase 2 | 155 | (Early Symptomatic AD, Eligible for AACG Study) | dogisimslb(kftbmqmqwz) = pvwjndjgdk csnmwpzofd (nuvbbkaucv, tpkfeykzli - gmxzhwmxpi) View more | - | 24 Aug 2020 | ||
(Early Symptomatic AD, Ineligible for AACG Study) | dogisimslb(kftbmqmqwz) = xsvvfmansr csnmwpzofd (nuvbbkaucv, pqtbpfpzyq - yyhevozvak) View more |